All ICAM-2 reagents are produced in house and quality controlled, including 9 ICAM-2 Antibody, 1 ICAM-2 ELISA, 39 ICAM-2 Gene, 1 ICAM-2 IPKit, 4 ICAM-2 Lysate, 4 ICAM-2 Protein, 3 ICAM-2 qPCR. All ICAM-2 reagents are ready to use.
Recombinant ICAM-2 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc, C-cleavage, C-human IgG1-Fc & His, C-His.
ICAM-2antibodies are validated with different applications, which are IHC-P, ELISA(Cap), WB, ELISA, ELISA(Det), IP.
ICAM-2cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each ICAM-2 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
ICAM-2ELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
Intercellular adhesion molecule 2 (ICAM-2, CD102), belongs to the ICAM family consisting of three members identified as ligands for integrin receptors. It is a type I transmembrane glycoprotein with two Ig-like C2-type domains, and binds to the leukocyte integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). As a second ligand of leukocyte function-associated antigen-1, ICAM-2 functions as a costimulatory molecule for effector cells. ICAM-2 is mainly expressed on vascular endothelial and hematopoietic cells. Interactions of ICAM-2 and the integrin receptors mediate cell adhesion in a wide range of lymphocyte, monocyte, natural killer cell, and granulocytewith other cells, and play important roles in many adhesion-dependent immune and inflammation responses, such as T cell aggregation, NK-cell cytotoxicity and migration, lymphocyte recirculation, etc. Serum levels of ICAM-2 correlated significantly with the inflammatory and course sequences of trichinosis in mice and had a similar relation with blood eosinophilia. So, estimation of ICAM-2 serum levels may prove useful in diagnosis of trichinosis recent infections, and in monitoring the prognosis and response to treatment.